FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1936707420> ?p ?o ?g. }

• W1936707420 abstract "Background As Parkinson's disease progresses the control of the symptoms often requires the addition of other drugs to levodopa. The principle aim of COMT inhibitor therapy is to increase the duration of effect of the levodopa dose and thus reduce the time patients spend in the relatively immobile 'off' phase. Objectives To compare the efficacy and safety of adjuvant COMT inhibitor therapy versus active comparators in patients with Parkinson's disease, already established on levodopa and suffering from motor complications. Search methods Electronic searches of the Cochrane Controlled Trials Register (The Cochrane Library Issue 1, 2003), MEDLINE (1966‐2003), EMBASE (1974‐2003), were conducted. Grey literature was hand searched and the reference lists of identified studies and reviews examined. The manufacturers of COMT inhibitors were contacted. Selection criteria Randomised controlled trials of adjuvant COMT inhibitor therapy versus an active comparator in patients with a clinical diagnosis of idiopathic Parkinson's disease and long‐term complications of levodopa therapy. Data collection and analysis Data was abstracted independently by the authors and differences settled by discussion. The outcome measures used included Parkinson's disease rating scales, levodopa dosage, 'off' time measurements and the frequency of withdrawals and adverse events. Main results Two trials were found that examined the efficacy of a COMT inhibitor against an active comparator (n = 349). Koller 1998 compared the efficacy of tolcapone versus pergolide (n = 203) over 12 weeks and TSG 1999 compared the efficacy of tolcapone versus bromocriptine (n = 146) over 8 weeks. No trials were found that compared entacapone with active comparators. Tolcapone produced similar benefits to bromocriptine in 'off' time reduction, motor impairment and disability ratings over three months of therapy. Tolcapone produced a greater reduction in levodopa dosage than bromocriptine. Tolcapone produced similar benefits to pergolide in levodopa dose reduction, motor impairment and disability ratings, and in generic health‐related quality of life scales over the first two months of therapy. Tolcapone produced a greater improvement in the disease‐specific quality of life scale PDQ‐39 than pergolide. Nausea, constipation and orthostatic complaints were greater with agonist therapy, but otherwise the frequency of adverse events and withdrawals from treatment were similar with the two classes of adjuvant medication. One patient had significantly elevated liver enzymes whilst on tolcapone, but otherwise the frequency of adverse events and withdrawals from treatment were similar. Authors' conclusions The two trials comparing tolcapone with the dopamine agonists bromocriptine and pergolide were underpowered to detect clinically relevant differences between them. This is based on medium‐term evidence. No evidence was found comparing entacapone with active comparators. Further larger and longer‐term trials are required to compare tolcapone with entacapone and COMT inhibitor therapy with alternative adjuvant classes of drug in later Parkinson's disease such as dopamine agonists and monoamine oxidase inhibitors." @default.
• W1936707420 created "2016-06-24" @default.
• W1936707420 creator A5005665397 @default.
• W1936707420 creator A5027662020 @default.
• W1936707420 creator A5056446117 @default.
• W1936707420 date "2004-10-18" @default.
• W1936707420 modified "2023-09-26" @default.
• W1936707420 title "Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease" @default.
• W1936707420 cites W1489370470 @default.
• W1936707420 cites W1732912328 @default.
• W1936707420 cites W1733091397 @default.
• W1936707420 cites W1868019775 @default.
• W1936707420 cites W2005606177 @default.
• W1936707420 cites W2030556805 @default.
• W1936707420 cites W2049451636 @default.
• W1936707420 cites W2078664151 @default.
• W1936707420 cites W2128573832 @default.
• W1936707420 cites W2132881915 @default.
• W1936707420 cites W2142960568 @default.
• W1936707420 cites W2886390611 @default.
• W1936707420 cites W4300901526 @default.
• W1936707420 doi "https://doi.org/10.1002/14651858.cd004553.pub2" @default.
• W1936707420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15495118" @default.
• W1936707420 hasPublicationYear "2004" @default.
• W1936707420 type Work @default.
• W1936707420 sameAs 1936707420 @default.
• W1936707420 citedByCount "6" @default.
• W1936707420 countsByYear W19367074202014 @default.
• W1936707420 crossrefType "journal-article" @default.
• W1936707420 hasAuthorship W1936707420A5005665397 @default.
• W1936707420 hasAuthorship W1936707420A5027662020 @default.
• W1936707420 hasAuthorship W1936707420A5056446117 @default.
• W1936707420 hasBestOaLocation W19367074202 @default.
• W1936707420 hasConcept C104317684 @default.
• W1936707420 hasConcept C126322002 @default.
• W1936707420 hasConcept C137183658 @default.
• W1936707420 hasConcept C168563851 @default.
• W1936707420 hasConcept C180754005 @default.
• W1936707420 hasConcept C185361966 @default.
• W1936707420 hasConcept C185592680 @default.
• W1936707420 hasConcept C197934379 @default.
• W1936707420 hasConcept C2776478404 @default.
• W1936707420 hasConcept C2776976799 @default.
• W1936707420 hasConcept C2778258207 @default.
• W1936707420 hasConcept C2778717949 @default.
• W1936707420 hasConcept C2779134260 @default.
• W1936707420 hasConcept C2779734285 @default.
• W1936707420 hasConcept C2780304432 @default.
• W1936707420 hasConcept C513476851 @default.
• W1936707420 hasConcept C535046627 @default.
• W1936707420 hasConcept C55493867 @default.
• W1936707420 hasConcept C71924100 @default.
• W1936707420 hasConceptScore W1936707420C104317684 @default.
• W1936707420 hasConceptScore W1936707420C126322002 @default.
• W1936707420 hasConceptScore W1936707420C137183658 @default.
• W1936707420 hasConceptScore W1936707420C168563851 @default.
• W1936707420 hasConceptScore W1936707420C180754005 @default.
• W1936707420 hasConceptScore W1936707420C185361966 @default.
• W1936707420 hasConceptScore W1936707420C185592680 @default.
• W1936707420 hasConceptScore W1936707420C197934379 @default.
• W1936707420 hasConceptScore W1936707420C2776478404 @default.
• W1936707420 hasConceptScore W1936707420C2776976799 @default.
• W1936707420 hasConceptScore W1936707420C2778258207 @default.
• W1936707420 hasConceptScore W1936707420C2778717949 @default.
• W1936707420 hasConceptScore W1936707420C2779134260 @default.
• W1936707420 hasConceptScore W1936707420C2779734285 @default.
• W1936707420 hasConceptScore W1936707420C2780304432 @default.
• W1936707420 hasConceptScore W1936707420C513476851 @default.
• W1936707420 hasConceptScore W1936707420C535046627 @default.
• W1936707420 hasConceptScore W1936707420C55493867 @default.
• W1936707420 hasConceptScore W1936707420C71924100 @default.
• W1936707420 hasIssue "1" @default.
• W1936707420 hasLocation W19367074201 @default.
• W1936707420 hasLocation W19367074202 @default.
• W1936707420 hasLocation W19367074203 @default.
• W1936707420 hasOpenAccess W1936707420 @default.
• W1936707420 hasPrimaryLocation W19367074201 @default.
• W1936707420 hasRelatedWork W1977455030 @default.
• W1936707420 hasRelatedWork W2051129186 @default.
• W1936707420 hasRelatedWork W2060750200 @default.
• W1936707420 hasRelatedWork W2062647602 @default.
• W1936707420 hasRelatedWork W2078664151 @default.
• W1936707420 hasRelatedWork W2163594315 @default.
• W1936707420 hasRelatedWork W2388961386 @default.
• W1936707420 hasRelatedWork W2398012774 @default.
• W1936707420 hasRelatedWork W2417056936 @default.
• W1936707420 hasRelatedWork W3207936603 @default.
• W1936707420 hasVolume "2010" @default.
• W1936707420 isParatext "false" @default.
• W1936707420 isRetracted "false" @default.
• W1936707420 magId "1936707420" @default.
• W1936707420 workType "article" @default.